TransCode Therapeutics Past Earnings Performance
Past criteria checks 0/6
TransCode Therapeutics's earnings have been declining at an average annual rate of -50.3%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-50.3%
Earnings growth rate
90.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -1,130.3% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
TransCode Therapeutics reports Q2 results
Aug 15TransCode files U.S. patent application for radiotherapy based cancer treatment
Jul 11We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely
Apr 01
Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation
Dec 15Revenue & Expenses BreakdownBeta
How TransCode Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -19 | 7 | 12 |
| 30 Sep 23 | 0 | -20 | 9 | 12 |
| 30 Jun 23 | 0 | -19 | 9 | 11 |
| 31 Mar 23 | 0 | -19 | 9 | 11 |
| 31 Dec 22 | 0 | -18 | 8 | 10 |
| 30 Sep 22 | 0 | -15 | 7 | 9 |
| 30 Jun 22 | 0 | -13 | 7 | 7 |
| 31 Mar 22 | 0 | -6 | 5 | 4 |
| 31 Dec 21 | 0 | -7 | 3 | 3 |
| 30 Sep 21 | 0 | -5 | 2 | 2 |
| 30 Jun 21 | 0 | -4 | 1 | 1 |
| 31 Mar 21 | 0 | -7 | 1 | 1 |
| 31 Dec 20 | 0 | -2 | 0 | 0 |
| 30 Sep 20 | 0 | -2 | 0 | 0 |
| 31 Dec 19 | 0 | -1 | 0 | 0 |
Quality Earnings: RNAZ is currently unprofitable.
Growing Profit Margin: RNAZ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RNAZ is unprofitable, and losses have increased over the past 5 years at a rate of 50.3% per year.
Accelerating Growth: Unable to compare RNAZ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RNAZ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: RNAZ has a negative Return on Equity (-1130.3%), as it is currently unprofitable.